Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAN-300/kg QW · 1 trial · 1 indication
Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.
| Arm | Type | Description |
|---|---|---|
| Cohort A - SAN-300 0.5 mg/kg QW | EXPERIMENTAL | SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks |
| Cohort B - SAN-300 1.0 mg/kg QW | EXPERIMENTAL | SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks |
| Cohort C - SAN-300 2.0 mg/kg QOW | EXPERIMENTAL | SAN-300 2.0 mg/kg subcutaneous every other week for six weeks |
| Cohort D - SAN-300 4.0 mg/kg QOW | EXPERIMENTAL | SAN-300 4.0 mg/kg subcutaneous every other week for six weeks |
| Cohort E - SAN-300 4.0 mg/kg QW | EXPERIMENTAL | SAN-300 4.0 mg/kg subcutaneous every other week for six weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo dosing |
| Name | Type | Description |
|---|---|---|
| SAN-300 0.5 mg/kg QW | DRUG | - |
| SAN-300 1.0 mg/kg QW | DRUG | - |
| SAN-300 2.0 mg/kg QOW | DRUG | - |
| SAN-300 4.0 mg/kg QOW | DRUG | - |
| SAN-300 4.0 mg/kg QW | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Diagnosed with RA for ≥ 6 months according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria 2010 2. 18 to 75 years of age, inclusive, at the time of informed consent 3. Swollen joint count of ≥ 6 (66-joint count) and...
Top 20 of 28 competitors
SAN-300/kg QW is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with rheumatoid arthritis to evaluate its safety and efficacy.
SAN-300/kg QW is being developed by Bausch Health Companies Inc., a company listed on the stock exchange under the ticker symbol BHC. The drug is currently in Phase 2 clinical development for the treatment of rheumatoid arthritis.
SAN-300/kg QW is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of rheumatoid arthritis and has not yet been approved by regulatory authorities. The drug is still in clinical trials and its safety and efficacy have not been fully established.
SAN-300/kg QW has been studied in one completed Phase 2 clinical trial with the identifier NCT02047604. This trial, titled "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis," enrolled 41 participants in the United States and was a randomized, double-blind, placebo-controlled study.
SAN-300/kg QW is a dosing regimen of the drug SAN-300, where the drug is administered once weekly. The clinical trial for SAN-300/kg QW, NCT02047604, evaluated escalating doses of SAN-300 in patients with rheumatoid arthritis. The drug is being developed by Bausch Health Companies Inc.